Navigating 6 Analyst Ratings For Abbott Laboratories
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Abbott Laboratories (NYSE:ABT) over the past three months, with a range of bullish to indifferent opinions. The average 12-month price target has increased by 2.95% to $126.83. Abbott's financial performance shows strong net margins and efficient asset management, despite lower revenue growth compared to peers.
September 26, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott Laboratories has received mixed analyst ratings, with a slight increase in the average price target. The company's strong net margins and efficient asset management are positive indicators, though revenue growth lags behind peers.
The mixed analyst ratings indicate varied expectations, but the increase in the average price target suggests a positive outlook. Abbott's strong financial metrics, such as net margins and asset management, support a favorable short-term impact, despite slower revenue growth compared to peers.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100